Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment

Cancer Cell

Volumn 32, Issue 6, 2017, Pages 777-791.e6

  Turaj, Anna H ^a   Hussain, Khiyam ^a   Cox, Kerry L ^a   Rose Zerilli, Matthew J J ^a   Testa, James ^b   Dahal, Lekh N ^a   Chan, H T Claude ^a   James, Sonya ^a   Field, Vikki L ^a   Carter, Matthew J ^a   Kim, Hyung J ^a   West, Jonathan J ^a   Thomas, Lawrence J ^b   He, Li Zhen ^b   Keler, Tibor ^b   Johnson, Peter W M ^a   Al Shamkhani, Aymen ^a   Thirdborough, Stephen M ^a   Beers, Stephen A ^a   Cragg, Mark S ^a   Glennie, Martin J ^a   Lim, Sean H ^a   more..

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b Celldex Therapeutics Inc   (United Kingdom)

Author keywords

cancer; CD20; CD27; macrophage; monoclonal antibody; NK cell; T cell

Indexed keywords

CD27 ANTIGEN; GAMMA INTERFERON; RITUXIMAB; VARLILUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; B16-F10 CELL LINE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; LYMPHOID CELL; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA SEQUENCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR VOLUME; AGONISTS; ANIMAL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOMA; MACROPHAGE ACTIVATION; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOMA; MACROPHAGE ACTIVATION; MICE; MICE, TRANSGENIC; TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 7;

EID: 85035754258     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.11.001     Document Type: Article

References (59)

1. Akiba, H., Nakano, H., Nishinaka, S., Shindo, M., Kobata, T., Atsuta, M., Morimoto, C., Ware, C.F., Malinin, N.L., Wallach, D., et al. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J. Biol. Chem. 273 (1998), 13353–13358.
2. al-Shamkhani, A., Birkeland, M.L., Puklavec, M., Brown, M.H., James, W., Barclay, A.N., OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand. Eur. J. Immunol. 26 (1996), 1695–1699.
3. Arens, R., Tesselaar, K., Baars, P.A., van Schijndel, G.M., Hendriks, J., Pals, S.T., Krimpenfort, P., Borst, J., van Oers, M.H., van Lier, R.A., Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 15 (2001), 801–812.
4. Beers, S.A., Chan, C.H., James, S., French, R.R., Attfield, K.E., Brennan, C.M., Ahuja, A., Shlomchik, M.J., Cragg, M.S., Glennie, M.J., Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 112 (2008), 4170–4177.
5. Beers, S.A., French, R.R., Chan, H.T., Lim, S.H., Jarrett, T.C., Vidal, R.M., Wijayaweera, S.S., Dixon, S.V., Kim, H., Cox, K.L., et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115 (2010), 5191–5201.
6. Biburger, M., Aschermann, S., Schwab, I., Lux, A., Albert, H., Danzer, H., Woigk, M., Dudziak, D., Nimmerjahn, F., Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35 (2011), 932–944.
7. Bichi, R., Shinton, S.A., Martin, E.S., Koval, A., Calin, G.A., Cesari, R., Russo, G., Hardy, R.R., Croce, C.M., Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc. Natl. Acad. Sci. USA 99 (2002), 6955–6960.
8. Biswas, S.K., Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11 (2010), 889–896.
9. Brezinsky, S.C., Chiang, G.G., Szilvasi, A., Mohan, S., Shapiro, R.I., MacLean, A., Sisk, W., Thill, G., A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity. J. Immunol. Methods 277 (2003), 141–155.
10. Burris, H.A., Infante, J.A., Ansell, S.M., Nemunaitis, J.J., Weiss, G.R., Villalobos, V.M., Sikic, B.I., Taylor, M.H., Northfelt, D.W., Carson, W.E., et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. J. Clin. Oncol. 35 (2017), 2028–2036.
11. Carr, J.M., Carrasco, M.J., Thaventhiran, J.E., Bambrough, P.J., Kraman, M., Edwards, A.D., Al-Shamkhani, A., Fearon, D.T., CD27 mediates interleukin-2-independent clonal expansion of the CD8+ T cell without effector differentiation. Proc. Natl. Acad. Sci. USA 103 (2006), 19454–19459.
12. Carter, M.J., Cox, K.L., Blakemore, S.J., Turaj, A.H., Oldham, R.J., Dahal, L.N., Tannheimer, S., Forconi, F., Packham, G., Cragg, M.S., PI3Kdelta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis. Leukemia 31 (2016), 1423–1433.
13. Cobb, L.M., Glennie, M.J., McBride, H.M., Breckon, G., Richardson, T.C., Characterisation of a new murine B cell lymphoma. Br. J. Cancer 54 (1986), 807–818.
14. Dahal, L.N., Dou, L., Hussain, K., Liu, R., Earley, A., Cox, K.L., Murinello, S., Tracy, I., Forconi, F., Steele, A.J., et al. STING activation reverses lymphoma-mediated resistance to antibody immunotherapy. Cancer Res. 77 (2017), 3619–3631.
15. de Jong, R., Loenen, W.A., Brouwer, M., van Emmerik, L., de Vries, E.F., Borst, J., van Lier, R.A., Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors. J. Immunol. 146 (1991), 2488–2494.
16. French, R.R., Taraban, V.Y., Crowther, G.R., Rowley, T.F., Gray, J.C., Johnson, P.W., Tutt, A.L., Al-Shamkhani, A., Glennie, M.J., Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 109 (2007), 4810–4815.
17. George, A.J., McBride, H.M., Glennie, M.J., Smith, L.J., Stevenson, F.K., Monoclonal antibodies raised against the idiotype of the murine B cell lymphoma, BCL1 act primarily with heavy chain determinants. Hybridoma 10 (1991), 219–227.
18. Gill, S., Vasey, A.E., De Souza, A., Baker, J., Smith, A.T., Kohrt, H.E., Florek, M., Gibbs, K.D. Jr., Tate, K., Ritchie, D.S., Negrin, R.S., Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood 119 (2012), 5758–5768.
19. Gong, Q., Ou, Q., Ye, S., Lee, W.P., Cornelius, J., Diehl, L., Lin, W.Y., Hu, Z., Lu, Y., Chen, Y., et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174 (2005), 817–826.
20. Gravestein, L.A., Amsen, D., Boes, M., Calvo, C.R., Kruisbeek, A.M., Borst, J., The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2. Eur. J. Immunol. 28 (1998), 2208–2216.
21. Guirnalda, P., Wood, L., Goenka, R., Crespo, J., Paterson, Y., Interferon gamma-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with Listeria monocytogenes. Oncoimmunology, 2, 2013, e25752.
22. Gul, N., Babes, L., Siegmund, K., Korthouwer, R., Bogels, M., Braster, R., Vidarsson, G., ten Hagen, T.L., Kubes, P., van Egmond, M., Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J. Clin. Invest. 124 (2014), 812–823.
23. Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F., Tedder, T.F., Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203 (2006), 743–753.
24. He, L.Z., Prostak, N., Thomas, L.J., Vitale, L., Weidlick, J., Crocker, A., Pilsmaker, C.D., Round, S.M., Tutt, A., Glennie, M.J., et al. Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice. J. Immunol. 191 (2013), 4174–4183.
25. Heng, T.S., Painter, M.W., Immunological Genome Project Consortium. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9 (2008), 1091–1094.
26. Huntington, N.D., Tabarias, H., Fairfax, K., Brady, J., Hayakawa, Y., Degli-Esposti, M.A., Smyth, M.J., Tarlinton, D.M., Nutt, S.L., NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J. Immunol. 178 (2007), 4764–4770.
27. Izawa, K., Martin, E., Soudais, C., Bruneau, J., Boutboul, D., Rodriguez, R., Lenoir, C., Hislop, A.D., Besson, C., Touzot, F., et al. Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection. J. Exp. Med. 214 (2017), 73–89.
28. Keller, A.M., Schildknecht, A., Xiao, Y., van den Broek, M., Borst, J., Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. Immunity 29 (2008), 934–946.
29. Kelly, J.M., Darcy, P.K., Markby, J.L., Godfrey, D.I., Takeda, K., Yagita, H., Smyth, M.J., Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3 (2002), 83–90.
30. Kohrt, H.E., Houot, R., Goldstein, M.J., Weiskopf, K., Alizadeh, A.A., Brody, J., Muller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117 (2011), 2423–2432.
31. Loetscher, M., Gerber, B., Loetscher, P., Jones, S.A., Piali, L., Clark-Lewis, I., Baggiolini, M., Moser, B., Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184 (1996), 963–969.
32. Malaise, M., Rovira, J., Renner, P., Eggenhofer, E., Sabet-Baktach, M., Lantow, M., Lang, S.A., Koehl, G.E., Farkas, S.A., Loss, M., et al. KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma. J. Immunol. 192 (2014), 1954–1961.
33. Minard-Colin, V., Xiu, Y., Poe, J.C., Horikawa, M., Magro, C.M., Hamaguchi, Y., Haas, K.M., Tedder, T.F., Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 112 (2008), 1205–1213.
34. Ohradanova-Repic, A., Machacek, C., Fischer, M.B., Stockinger, H., Differentiation of human monocytes and derived subsets of macrophages and dendritic cells by the HLDA10 monoclonal antibody panel. Clin. Transl. Immunology, 5, 2016, e55.
35. Otten, M.A., van der Bij, G.J., Verbeek, S.J., Nimmerjahn, F., Ravetch, J.V., Beelen, R.H., van de Winkel, J.G., van Egmond, M., Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J. Immunol. 181 (2008), 6829–6836.
36. Ramakrishnan, P., Wang, W., Wallach, D., Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity 21 (2004), 477–489.
37. Robbins, S.H., Tessmer, M.S., Mikayama, T., Brossay, L., Expansion and contraction of the NK cell compartment in response to murine cytomegalovirus infection. J. Immunol. 173 (2004), 259–266.
38. Roberts, D.J., Franklin, N.A., Kingeter, L.M., Yagita, H., Tutt, A.L., Glennie, M.J., Bullock, T.N., Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J. Immunother. 33 (2010), 769–779.
39. Robinson, M.D., McCarthy, D.J., Smyth, G.K., edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26 (2010), 139–140.
40. Rowley, T.F., Al-Shamkhani, A., Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo. J. Immunol. 172 (2004), 6039–6046.
41. Slavin, S., Strober, S., Spontaneous murine B-cell leukaemia. Nature 272 (1978), 624–626.
42. Souza-Fonseca-Guimaraes, F., Blake, S.J., Makkouk, A., Chester, C., Kohrt, H.E., Smyth, M.J., Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity. Oncoimmunology, 5, 2016, e1192740.
43. Sugita, K., Robertson, M.J., Torimoto, Y., Ritz, J., Schlossman, S.F., Morimoto, C., Participation of the CD27 antigen in the regulation of IL-2-activated human natural killer cells. J. Immunol. 149 (1992), 1199–1203.
44. Takeda, K., Oshima, H., Hayakawa, Y., Akiba, H., Atsuta, M., Kobata, T., Kobayashi, K., Ito, M., Yagita, H., Okumura, K., CD27-mediated activation of murine NK cells. J. Immunol. 164 (2000), 1741–1745.
45. Taraban, V.Y., Rowley, T.F., Tough, D.F., Al-Shamkhani, A., Requirement for CD70 in CD4+ Th cell-dependent and innate receptor-mediated CD8+ T cell priming. J. Immunol. 177 (2006), 2969–2975.
46. Taskinen, M., Karjalainen-Lindsberg, M.L., Nyman, H., Eerola, L.M., Leppa, S., A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin. Cancer Res. 13 (2007), 5784–5789.
47. Tipton, T.R., Mockridge, C.I., French, R.R., Tutt, A.L., Cragg, M.S., Beers, S.A., Anti-mouse FcgammaRIV antibody 9E9 also blocks FcgammaRIII in vivo. Blood 126 (2015), 2643–2645.
48. Tipton, T.R., Roghanian, A., Oldham, R.J., Carter, M.J., Cox, K.L., Mockridge, C.I., French, R.R., Dahal, L.N., Duriez, P.J., Hargreaves, P.G., et al. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood 125 (2015), 1901–1909.
49. Turaj, A.H., Dahal, L.N., Beers, S.A., Cragg, M.S., Lim, S.H., TLR-3/9 agonists synergize with anti-ErbB2 mAb-letter. Cancer Res. 77 (2017), 3376–3378.
50. Tutt, A.L., French, R.R., Illidge, T.M., Honeychurch, J., McBride, H.M., Penfold, C.A., Fearon, D.T., Parkhouse, R.M., Klaus, G.G., Glennie, M.J., Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 161 (1998), 3176–3185.
51. Uchida, J., Hamaguchi, Y., Oliver, J.A., Ravetch, J.V., Poe, J.C., Haas, K.M., Tedder, T.F., The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199 (2004), 1659–1669.
52. van Lier, R.A., Borst, J., Vroom, T.M., Klein, H., Van Mourik, P., Zeijlemaker, W.P., Melief, C.J., Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J. Immunol. 139 (1987), 1589–1596.
53. van Montfrans, J.M., Hoepelman, A.I., Otto, S., van Gijn, M., van de Corput, L., de Weger, R.A., Monaco-Shawver, L., Banerjee, P.P., Sanders, E.A., Jol-van der Zijde, C.M., et al. CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J. Allergy Clin. Immunol. 129 (2012), 787–793.e6.
54. Vitale, L.A., He, L.Z., Thomas, L.J., Widger, J., Weidlick, J., Crocker, A., O'Neill, T., Storey, J., Glennie, M.J., Grote, D.M., et al. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin. Cancer Res. 18 (2012), 3812–3821.
55. Weiner, G.J., Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 15 (2015), 361–370.
56. Weiskopf, K., Weissman, I.L., Macrophages are critical effectors of antibody therapies for cancer. MAbs 7 (2015), 303–310.
57. Williams, E.L., Tutt, A.L., Beers, S.A., French, R.R., Chan, C.H., Cox, K.L., Roghanian, A., Penfold, C.A., Butts, C.L., Boross, P., et al. Immunotherapy targeting inhibitory Fcgamma receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization. J. Immunol. 191 (2013), 4130–4140.
58. Xiao, Y., Hendriks, J., Langerak, P., Jacobs, H., Borst, J., CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation. J. Immunol. 172 (2004), 7432–7441.
59. Yakes, F.M., Chinratanalab, W., Ritter, C.A., King, W., Seelig, S., Arteaga, C.L., Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62 (2002), 4132–4141.